A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer by Lori J. Goldstein, Raymond P. Perez, Denise Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato, Jenny C. Chang

Get full text